ANO1 overexpression not only serves as an independent prognostic biomarker for poor prognosis in HNSCC, aiding in patient risk stratification and survival prediction, but also plays a critical role in radiotherapy and cisplatin resistance. This evidence concerns the gene ANO1 and head and neck squamous cell carcinoma.